Skip to main content
Fig. 1 | Trials

Fig. 1

From: A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer’s disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial

Fig. 1

Trial schedule. MMSE: Mini-Mental State Examination, 15-VLT: 15-word Verbal Learning Task, CDR: Clinical Dementia Rating, LDST: Letter Digit Substitution Task, ADAS-Cog: Alzheimer’s Disease Assessment Scale – Cognitive subscale, TMT: Trail Making Test, HADS: Hospital Anxiety Depression Scale, EQ-5D: EuroQol – 5 Dimensions, QoL-AD: Quality of Life Alzheimer’s Disease, NPI: Neuropsychiatric Inventory, ADCS-ADL: Alzheimer’s Disease Cooperative Study—Activities of Daily Living, ECG: Electrocardiogram, ROS: reactive oxygen species

Back to article page

Trials

ISSN: 1745-6215